We and others have shown that an elevated glycosyltransferase UGT2B17 expression identifies a subgroup of CLL patients with shorter treatment-free survival and overall survival, independent of other risk factors in multivariate analyses [6,7,8,9]. The gene discussed is UGT2B17; the disease is B-cell chronic lymphocytic leukemia.